Abnormal nuclear factor erythroid 2-related factor 2 expression (Nrf2, the master regulator of the antioxidant defense system) is associated with melanoma incidence and is co-opted during cancer progression, with its levels varying by cancer stage [41]. This evidence concerns the gene NFE2L2 and cancer.